Paper card · curated
Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease
Borrelli F, Fasolino I, Romano B, Capasso R, Maiello F, et al.
Biochemical Pharmacology · 2013
Abstract excerpt
Investigated CBG in mouse models of colitis. CBG reduced inflammation markers (myeloperoxidase activity, iNOS expression, IL-1β/IFN-γ release) at doses of 1-30 mg/kg ip. Mechanism appears to involve CB2 receptor activation and α2-adrenoceptor agonism. CBG is one of the more-studied minor cannabinoids; clinical-trial evidence in humans remains thin.
Excerpt from the published abstract. Full paper at the journal link below.
Joe's notes
How to read this paper
CBG marketing has run ahead of the clinical evidence. Preclinical mechanism is plausible and interesting; we don't yet have RCT data in humans matching the consumer-marketing claims. Treat the evidence honestly when discussing CBG products.
Read the paper
FDA disclaimer
Research papers in this library describe published scientific findings. They are not therapeutic claims. These statements have not been evaluated by the FDA. Compounds discussed in any paper are not intended to diagnose, treat, cure, or prevent any disease. Talk to a healthcare provider before making decisions about supplements.